Discontinued — last reported Q2 '22
Business Segments · Revenue
Interventional — Revenue
Becton, Dickinson and Company Interventional — Revenue decreased by 71.2% to $1.36B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 69.7%, from $4.48B to $1.36B. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ3 2015
Last reportedQ2 2022
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market share or demand for interventional medical products, while a decrease may signal competitive pressure or market saturation.
Detailed definition
This metric represents the total gross sales generated by the Interventional business segment, which focuses on surgical...
Peer comparison
Comparable to segment-level revenue reporting in diversified medical device companies like Medtronic or Boston Scientific.
Metric ID:
bdx_segment_interventional_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.61B | $1.08B | $4.30B | $1.07B | $4.72B | $1.12B | $4.75B | $1.11B | $4.64B | $1.14B | $4.76B | $1.10B | $4.59B | $1.13B | $4.82B | $1.19B | $4.88B | $1.22B | $5.09B | $1.20B | $4.71B | $1.19B | $5.05B | $1.29B | $4.99B | $1.24B | $5.44B | $1.26B | $5.17B | $1.26B | $4.48B | $1.26B | $5.51B | $1.33B | $6.68B | $1.37B | $5.25B | $1.33B | $4.71B | $1.36B |
| QoQ Change | — | -76.5% | +297.6% | -75.1% | +340.5% | -76.4% | +326.0% | -76.6% | +317.7% | -75.4% | +316.9% | -77.0% | +318.4% | -75.4% | +327.0% | -75.4% | +311.3% | -75.0% | +317.7% | -76.4% | +291.2% | -74.8% | +324.7% | -74.4% | +286.2% | -75.2% | +338.5% | -76.8% | +310.2% | -75.7% | +256.4% | -71.8% | +335.8% | -75.9% | +403.2% | -79.5% | +283.9% | -74.7% | +254.4% | -71.2% |
| YoY Change | — | — | — | — | — | — | — | — | +0.7% | -75.2% | +10.7% | -74.5% | -2.8% | -76.1% | +1.5% | -75.0% | +5.1% | -73.8% | +6.8% | -74.7% | +2.6% | -74.1% | +4.6% | -73.2% | +2.3% | -74.6% | +6.9% | -75.2% | +9.8% | -73.3% | -11.2% | -74.9% | +10.4% | -73.4% | +22.9% | -74.8% | +1.6% | -74.3% | +5.2% | -69.7% |
Range$1.07B – $6.68B
CAGR-11.8%
Avg YoY Growth-34.7%
Median YoY Growth-40.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's interventional — revenue?
- Becton, Dickinson and Company (BDX) reported interventional — revenue of $1.36B in Q1 2026.
- How has Becton, Dickinson and Company's interventional — revenue changed year-over-year?
- Becton, Dickinson and Company's interventional — revenue decreased by 69.7% year-over-year, from $4.48B to $1.36B.
- What does interventional — revenue mean?
- Total revenue generated specifically by the Interventional business segment.